文献速递妇科产科

绝经激素治疗与心血管代谢病风险:现有证据与未来方向

Hormone Replacement Therapy for Menopausal Symptoms and the Risk of Cardiometabolic Disease: Current Evidence and Future Directions.
PubMed 文献 · BJOG · 2026-03-11

本文为叙述性综述,讨论绝经激素治疗(HRT)对心血管代谢危险因素及冠心病、卒中和代谢功能障碍相关脂肪性肝病(MASLD)风险的影响。现有证据提示HRT可能影响内脏脂肪、血脂、血压和血糖控制,且雌激素给药途径、启动时机和孕激素类型均可能影响上述结局。

要点

  • HRT可能影响内脏脂肪、血脂、血压和血糖控制等代谢危险因素。
  • 随机对照试验证据细化了对HRT与冠心病、卒中风险关系的理解。
  • 雌激素给药途径、启动时机和孕激素类型可能影响HRT的心血管代谢效应。

核心结论

  • 现有证据提示HRT可能影响多种心血管代谢危险因素及冠心病、卒中和MASLD风险,但存在不确定性,需进一步研究。

研究设计与样本

  • 叙述性综述,未报告系统检索范围或样本量。

主要发现

  • HRT可能影响内脏脂肪积累、血脂谱不良变化、血压和血糖控制等代谢危险因素。
  • 随机对照试验结果细化了对HRT与冠心病和卒中结局关系的理解。
  • 近期研究强调绝经对MASLD发生和严重程度的影响,但HRT背景下研究不足。
  • 雌激素给药途径、启动时机和孕激素类型均可能影响HRT对上述结局的作用。

临床怎么用

  • HRT主要用于控制绝经症状,启动和继续治疗时应讨论其对心血管代谢的影响以助知情决策。
  • 选择HRT方案时需考虑雌激素给药途径、启动时机和孕激素类型对心血管代谢结局的潜在影响。

局限性

  • 叙述性综述,未报告系统检索策略。
  • HRT与MASLD的关系研究不足。
  • HRT对心血管代谢结局的影响存在不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The transition through menopause is accompanied by a series of adverse metabolic changes which are associated with an increased risk of cardiometabolic disease, a major cause of mortality in women after midlife. Whilst the indication for menopausal hormone replacement therapy (HRT) is the control of menopausal symptoms, understanding and discussing the cardiometabolic impacts of HRT are necessary to facilitate informed decision-making at treatment initiation and continuation, and to select appropriate regimens. METHODOLOGY: A narrative review. RESULTS: Existing evidence suggests that HRT is likely to impact the development of metabolic risk factors including visceral fat accumulation, adverse changes in lipid profile, blood pressure and glycaemic control. Findings from randomised controlled trials have refined our understanding of the impact of HRT on cardiometabolic outcomes including coronary heart disease and stroke. Furthermore, recent research has highlighted the impact of the menopause on the development and severity of metabolic dysfunction-associated steatotic liver disease (MASLD) that has been poorly studied in the context of HRT. The route of oestrogen administration, timing of initiation and type of progestogen are all likely to affect the impact of HRT on many of these outcomes. There has recently been extensive media interest in HRT in some countries resulting in increased prescription rates. Understanding the impact of HRT on cardiometabolic risk is therefore particularly important. In this narrative review, we discuss the existing evidence and clinical guidelines on the effect of HRT on cardiometabolic risk factors and the risk of coronary heart disease, stroke and MASLD, highlighting areas of uncertainty and priorities for further research.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Dong J, Hillman S, Dixon S, et al. Hormone Replacement Therapy for Menopausal Symptoms and the Risk of Cardiometabolic Disease: Current Evidence and Future Directions. BJOG. 2026. PMID: 41808572. doi:10.1111/1471-0528.70214

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。